Literature DB >> 18022293

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.

Menira Souza1, Veronica Costantini, Marli S P Azevedo, Linda J Saif.   

Abstract

We inoculated gnotobiotic pigs orally/intranasally with human norovirus GII.4 HS66 strain virus-like particles (VLP) and immunostimulating complexes (ISCOM) or mutant E. coli LT toxin (mLT, R192G) as mucosal adjuvants, then assessed intestinal and systemic antibody and cytokine responses and homologous protection. Both vaccines induced high rates of seroconversion (100%) and coproconversion (75-100%). The VLP+mLT vaccine induced Th1/Th2 serum cytokines and cytokine secreting cells, whereas the VLP+ISCOM vaccine induced Th2 biased responses with significantly elevated IgM, IgA and IgG antibody-secreting cells in intestine. Nevertheless, both vaccines induced increased protection rates against viral shedding and diarrhea (75-100%) compared to controls; however, only 57% of controls shed virus.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18022293      PMCID： PMC4094375          DOI： 10.1016/j.vaccine.2007.09.040

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  37 in total

1.  Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines.

Authors:  Lijuan Yuan; Shin-Ichi Ishida; Shinjiro Honma; John T Patton; Douglas C Hodgins; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2004-04-29       Impact factor: 5.226

2.  Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes.

Authors:  Cristiana Iosef; Trang Van Nguyen; Kwang il Jeong; Karin Bengtsson; Bror Morein; Yunjeong Kim; Kyeong Ok Chang; Marli S P Azevedo; Lijuan Yuan; Paul Nielsen; Linda J Saif
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

3.  Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.

Authors:  J M Ball; D Y Graham; A R Opekun; M A Gilger; R A Guerrero; M K Estes
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

4.  Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus.

Authors:  M S P Azevedo; L Yuan; S Pouly; A M Gonzales; K I Jeong; T V Nguyen; L J Saif
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Cellular and humoral immunity following Snow Mountain virus challenge.

Authors:  Lisa Lindesmith; Christine Moe; Jacques Lependu; Jeffrey A Frelinger; John Treanor; Ralph S Baric
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

7.  Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.

Authors:  Marli S P Azevedo; Lijuan Yuan; Cristiana Iosef; Kyeong-Ok Chang; Yunjeong Kim; Trang Van Nguyen; Linda J Saif
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

8.  Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain).

Authors:  M Souza; S M Cheetham; M S P Azevedo; V Costantini; L J Saif
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

9.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.

Authors:  R A Guerrero; J M Ball; S S Krater; S E Pacheco; J D Clements; M K Estes
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103
View more
  30 in total

1.  Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010.

Authors:  Sayaka Takanashi; Qiuhong Wang; Ning Chen; Quan Shen; Kwonil Jung; Zhenwen Zhang; Masaru Yokoyama; Lisa C Lindesmith; Ralph S Baric; Linda J Saif
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.

Authors:  Tammy Bui; Jacob Kocher; Yanru Li; Ke Wen; Guohua Li; Fangning Liu; Xingdong Yang; Tanya LeRoith; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

Review 3.  Advances in norovirus biology.

Authors:  Stephanie M Karst; Christiane E Wobus; Ian G Goodfellow; Kim Y Green; Herbert W Virgin
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

Review 4.  Vaccine against norovirus.

Authors:  Ming Tan; Xi Jiang
Journal:  Hum Vaccin Immunother       Date:  2014-05-05       Impact factor: 3.452

5.  Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Authors:  Shin-Hee Kim; Shun Chen; Xi Jiang; Kim Y Green; Siba K Samal
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Authors:  Jacob Kocher; Tammy Bui; Ernawati Giri-Rachman; Ke Wen; Guohua Li; Xingdong Yang; Fangning Liu; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Chimpanzees as an animal model for human norovirus infection and vaccine development.

Authors:  Karin Bok; Gabriel I Parra; Tanaji Mitra; Eugenio Abente; Charlene K Shaver; Denali Boon; Ronald Engle; Claro Yu; Albert Z Kapikian; Stanislav V Sosnovtsev; Robert H Purcell; Kim Y Green
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

8.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  The state of norovirus vaccines.

Authors:  Kari Debbink; Lisa C Lindesmith; Ralph S Baric
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

10.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.